Company intelligence / Profile preview
Alveron Pharma
Nijmegen, Netherlandsalveron.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing OKL-1111, a cyclodextrin-based drug designed to treat hemorrhagic stroke by reversing anticoagulant effects with a universal mode of action. The drug enables administration within 10 minutes of a diagnosing CT scan and can reverse the effects of clopidogrel, a major platelet inhibitor for which there is currently no antidote[3][5].
- Therapeutic areas
- NeurologyHematology
- Modalities
- Small molecules (cyclodextrin-based drugs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Sanquin (the Dutch Blood Foundation)
Beyond the preview
Go deeper on Alveron Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alveron Pharma.